# Progestin-primed ovarian stimulation protocol in patients undergoing assisted reproductive technology

**Authors:** Shanqin Qi, Haiyan Yu, Xiaojing Yang, Qinghan Shi, Liu Yang, Kehua Wang

PMC · DOI: 10.3389/frph.2025.1719930 · Frontiers in Reproductive Health · 2026-01-23

## TL;DR

This paper evaluates a new ovarian stimulation protocol using progestin during IVF, showing it is safe and effective compared to traditional methods.

## Contribution

The study introduces and evaluates the progestin-primed ovarian stimulation (PPOS) protocol as a novel approach in assisted reproductive technology.

## Key findings

- PPOS provides better control over the LH surge and reduces the risk of ovarian hyperstimulation syndrome.
- PPOS achieves comparable clinical pregnancy rates and neonatal outcomes to traditional protocols.
- The protocol does not negatively affect oocyte development or embryo quality.

## Abstract

To evaluate the effectiveness and safety of the novel protocol—progestin-primed ovarian stimulation (PPOS) protocol during controlled ovarian hyperstimulation (COH), in patients undergoing in vitro fertilization/intracytopalsmic sperm injection and embryo transfer (IVF/ICSI-ET).

By reviewing and analyzing published studies since PPOS protocol was firstly reported in 2015, we compared differences in ovarian stimulation characteristics, embryological features, pregnancy rates, and neonatal outcomes between PPOS protocol and conventional regimens employed in assisted reproductive technology (ART), and discussed the advantages and limitations of PPOS protocol.

By adding exogenous progestin (P) during early follicular phase, PPOS scheme provide robust control over preovulatory luteinizing hormone (LH) surge and spontaneous ovulation, which promote oocyte maturation and recovery. Compared to various traditional protocols, PPOS achieved promising clinical pregnancy results, and equivalent rates of birth defect and congenital malformation. Moreover, it possessed significantly lower risk of ovarian hyperstimlation syndrome (OHSS).

Not inferior or comparable outcomes indicated that PPOS protocol is a competent alternative for ART with no obviously detrimental impact on oocyte development and embryo quality.

## Linked entities

- **Chemicals:** progestin (PubChem CID 5994)
- **Diseases:** ovarian hyperstimulation syndrome (MONDO:0011972)

## Full-text entities

- **Diseases:** birth defect (MESH:D000014), OHSS (MESH:D010049), congenital malformation (OMIM:163000)
- **Chemicals:** P (MESH:D010758), LH (MESH:D007986)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12876159/full.md

## References

99 references — full list in the complete paper: https://tomesphere.com/paper/PMC12876159/full.md

---
Source: https://tomesphere.com/paper/PMC12876159